{"id":22525,"date":"2025-09-27T08:58:19","date_gmt":"2025-09-27T12:58:19","guid":{"rendered":"https:\/\/www.ices.on.ca\/?post_type=journal_article&#038;p=22525"},"modified":"2025-10-01T09:11:14","modified_gmt":"2025-10-01T13:11:14","slug":"practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\/","title":{"rendered":"Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI"},"content":{"rendered":"<p><strong>Background<\/strong> \u2014 Acute kidney injury (AKI) is a known immune related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further population-based data on AKI incidence, risk factors and practice patterns post-ICI therapy are needed.<\/p>\n<p><strong>Methods<\/strong> \u2014 We measured the cumulative incidence of AKI among advanced cancer patients while receiving ICI therapy and non-ICI systemic therapy in Ontario, Canada (2012\u20132018). Increase in serum creatinine was used to define AKI and graded according to event severity. Time to event modelling was used to compare the risk of developing AKI, pre-disposing factors and survival outcomes.<\/p>\n<p><strong>Results<\/strong> \u2014 We studied 16\u2009425 patients with advanced cancer receiving either ICI or non-ICI systemic therapy. Among 4\u2009380 patients receiving ICI therapy, the overall crude 4-year incidence of AKI (any stage) was 29% and severe AKI (\u2265 stage 2) was 7%. Characteristics associated with a higher risk of AKI included male sex, genitourinary (versus other) malignancy, the presence of hypertension, diabetes, chronic kidney disease, and prescription of a non-steroidal anti-inflammatory drug. The risk of experiencing AKI was significantly lower among patients treated with ICI versus non-ICI systemic therapy [adjusted hazards ratio (aHR) = 0.80, 95% confidence interval (CI) = 0.74\u20130.86, P-value &lt; 0.0001]. Among the 587 patients who experienced an AKI and were both alive and discontinued ICI therapy within 30 days, 54 (9%) were re-challenged with ICI in the following 6 months and 24 (44%) had a recurrent AKI event. Patients who were re-challenged with ICI therapy had improved overall survival as compared to patients that received other non-ICI systemic therapy (aHR = 0.38; 95% CI: 0.22\u20130.67, P-value &lt; 0.001).<\/p>\n<p><strong>Conclusion<\/strong> \u2014 Our real-world study demonstrates a modest risk for AKI among cancer patients receiving ICI therapy, lower than with exposure to other systemic cancer therapies. Among patients who developed AKI and stopped ICI therapy, re-challenge was uncommon but may warrant consideration for select patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Background \u2014 Acute kidney injury (AKI) is a known immune related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further population-based data on AKI incidence, risk factors and practice patterns post-ICI therapy are needed. Methods \u2014 We measured the cumulative incidence of AKI among advanced cancer patients while receiving ICI therapy and non-ICI systemic [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[38,56],"migration-helper-qa-sample-set":[],"class_list":["post-22525","journal_article","type-journal_article","status-publish","hentry","topic-cancer-and-cancer-screening","topic-pharmacoepidemiology-and-drug-safety"],"acf":{"citation":"Blanchette P, Reid J, Richard L, Shariff SZ, Raphael J, Earle CC, Garg AX, Kitchlu A. <em>Nephrol Dial Transplant<\/em>. 2025; gfaf191. Epub 2025 Sep 27.","source_url":"https:\/\/doi.org\/10.1093\/ndt\/gfaf191","ices_scientist":[1165,1359,13132,1225,1242],"site":[6739],"research_program":[6743],"news_release":"","journal_article":"","atlas":"","research_report":"","infographic":"","video":"","downloads":null,"links":null,"sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":"","previous_url":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI<\/title>\n<meta name=\"description\" content=\"Background \u2014 Acute kidney injury (AKI) is a known immune related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI\" \/>\n<meta property=\"og:description\" content=\"Background \u2014 Acute kidney injury (AKI) is a known immune related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-01T13:11:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\\\/\",\"name\":\"ICES | Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2025-09-27T12:58:19+00:00\",\"dateModified\":\"2025-10-01T13:11:14+00:00\",\"description\":\"Background \u2014 Acute kidney injury (AKI) is a known immune related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI","description":"Background \u2014 Acute kidney injury (AKI) is a known immune related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI","og_description":"Background \u2014 Acute kidney injury (AKI) is a known immune related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2025-10-01T13:11:14+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\/","name":"ICES | Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2025-09-27T12:58:19+00:00","dateModified":"2025-10-01T13:11:14+00:00","description":"Background \u2014 Acute kidney injury (AKI) is a known immune related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/practice-patterns-and-outcomes-in-cancer-patients-developing-immune-checkpoint-inhibitors-related-aki\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/22525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6743"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6739"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1242"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1225"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/13132"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1359"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1165"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=22525"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=22525"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=22525"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=22525"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=22525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}